NOS3

Across TCGA pan-cancer cohorts, NOS3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NOS3 data layer compared with 26 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NOS3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NOS3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where NOS3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.909	0.707	.009	37	view →
LUAD	DFS	Median	II,III,IV	0.353	0.629	.011	8	view →
GBM	DFS	Quartile	All	0.558	0.257	.005	7	view →
PDAC	OS	Tertile	All	0.383	0.530	.020	6	view →
LSCC	DFS	Median	All	0.892	0.976	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NOS3–CCRCC (OS)

Open the CCRCC breakdown →